Psoriasis (PsO) is a common chronic relapsing inflammatory disease, induced by a combination of genetic and environmental effects, which seriously affects the quality of life of patients.Psoriasis Area and Severity Index（PASI score ） ，as the most common method used by clinicians to assess the severity of psoriasis and the effectiveness of treatment, has the disadvantage of being subjective and superficial.We are therefore committed to establishing an objective, real-time, repeatable, non-invasive, microscopic assessment using high-frequency ultrasound. This study will use high-frequency ultrasound to detect the patient's lesion site and the 2cm site next to the lesion once, and the study will continue to recruit for 6 months.
Patients who meet the medical criteria for plaque psoriasis
Those who voluntarily participate in this study and sign the informed consent form
Patients with other types of psoriasis
Those with other active medical conditions that may affect assessment
During a severe uncontrollable acute or chronic local or systemic infection
Those with severe mental illness, cognitive impairment, and incapacity for personal behavior that makes them unsuitable to participate in a clinical study
Patients aged 18-75 years with plaque psoriasis who meet inclusion and exclusion criteria
Cohort
Prospective
No intervention
Other interventionThis is an observational study, no intervention will be implemented.
High Frequency Ultrasound
epidermal thickness (unit mm) detected by Grayscale ultrasound
High Frequency Ultrasound
dermal thickness (unit mm) detected by Grayscale ultrasound
High Frequency Ultrasound
hypoechoic cord thickness between epidermis and dermis (unit mm) detected by Grayscale ultrasound
High Frequency Ultrasound
epidermal echo intensity detected by Grayscale ultrasound
Localized PASI
Same scoring criteria as PASI scores without area factors.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
